Guidelines for the use of second-generation long-acting antipsychotics | Zendy

Marek Jarema | Zendy; Adam Wichniak | Zendy; Dominika Dudek | Zendy; Jerzy Samochowiec | Zendy; Przemysław Bieńkowski | Zendy; Janusz Rybakowski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Guidelines for the use of second-generation long-acting antipsychotics

Author(s) -

Marek Jarema,

Adam Wichniak,

Dominika Dudek,

Jerzy Samochowiec,

Przemysław Bieńkowski,

Janusz Rybakowski

Publication year - 2015

Publication title -

psychiatria polska

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.414

H-Index - 22

eISSN - 2391-5854

pISSN - 0033-2674

DOI - 10.12740/pp/39370

Subject(s) - aripiprazole , olanzapine , risperidone , paliperidone , quetiapine , schizophrenia (object oriented programming) , medicine , paliperidone palmitate , psychiatry , antipsychotic , intensive care medicine , psychology

Long-acting injectable antipsychotics constitute a valuable alternative for the treatment of psychotic disorders, mainly schizophrenia. They assure a more stable drug level, improve treatment compliance, and increase the chances for favorable and long-lasting improvement. Additionally, the long-acting second-generation antipsychotics combine the values of long-acting injectable drugs with the values of atypical antipsychotics. Four second generation long-acting antipsychotics have been described: risperidone, olanzapine, aripiprazole and paliperidone. The indications for their use, treatment strategy, tolerance, and potential interactions are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research